Much of the GLP-1 compounding story covered elsewhere on this site is a distinctly American regulatory phenomenon. The compounded GLP-1 industry that scaled rapidly in the U.S. during 2022–2024 grew out of a specific structural feature of U.S. pharmacy law — the shortage-list exemption under Sections 503A and 503B of the FD&C Act — that doesn't have a direct equivalent in European Union regulation.
The structural difference
The European Union does not have a nationwide system equivalent to the U.S. 503A/503B framework for large-scale compounding.[1] Individual EU member states permit patient-specific pharmacy preparations under a doctor's prescription, but these exceptions are narrowly defined and tightly controlled compared to the U.S. system — there is no equivalent to the American 503B outsourcing facility model, where an FDA-registered entity compounds in bulk for distribution across multiple providers under a formal shortage-list or clinical-need pathway.
While many European countries permit patient-specific preparations under a doctor's prescription, these exceptions are narrowly defined and tightly controlled.
The EMA's new synthetic peptide guideline
In parallel with the U.S. 503B Bulks List proceedings, the EMA issued new guidance on synthetic peptides that formalizes a high quality and safety bar for legitimate peptide medicines entering the European market, while making it correspondingly more difficult for unauthorized products to circulate.[2] This guideline treats synthetic peptides with a level of regulatory scrutiny comparable to other complex pharmaceuticals — a structural choice that, combined with the absence of a large-scale compounding pathway, leaves noticeably less legal room for a compounded-GLP-1-style market to emerge in the EU the way it did in the U.S.
Where generic and biosimilar timelines diverge
Liraglutide's core patents have already expired in major markets (2023–2024), and European markets have moved faster than the U.S. on generic/biosimilar access — liraglutide generics have received EMA approval and are achieving formulary access in multiple EU countries, with visible price competition in tender markets, while U.S. generic entry for liraglutide was still developing as of mid-2026.[3] Semaglutide's composition-of-matter protection is expected to extend to roughly 2031–2032 in major markets, and tirzepatide's to approximately 2036, meaning the newer, more widely-used agents remain under patent protection in both jurisdictions for years yet.
Why this affects global access strategy, not just legal compliance
A oral GLP-1 pill priced aggressively through direct-to-consumer channels — the kind of pricing move some manufacturers have signaled interest in — could plausibly do more to expand global GLP-1 access than any single regulatory action, simply because it sidesteps the entire compounding-versus-brand-name access debate that dominates U.S. discourse. Regulatory harmonization discussions aside, price remains the variable most directly under manufacturer control.
A broader multi-jurisdiction trend
The EMA is not acting in isolation. The UK's MHRA, Health Canada, and Australia's TGA have each issued updated guidance on GLP-1 access, compounding, or peptide therapy within roughly the same twelve-month window as the U.S. 503B proceedings and the EMA's synthetic peptide guideline — suggesting a broadly convergent global regulatory response to the same underlying phenomenon (rapid GLP-1 demand growth and associated compounding/counterfeit risk), even where the specific legal mechanisms chosen differ by jurisdiction.[4]
This comparison covers structural/legal framework differences, not clinical approval divergence. Specific drug-by-drug approval timing and indication differences between FDA and EMA (which sometimes approve the same GLP-1 medication for different specific populations or at different times) are a separate analysis from the compounding/manufacturing framework comparison covered here.
Compare GLP-1 telehealth providers
Source GLP-1 tracks pricing, licensing, and provider structure across the market.